{"id":33157,"date":"2020-07-17T17:04:52","date_gmt":"2020-07-17T15:04:52","guid":{"rendered":"http:\/\/shekulliagency.com\/?p=33157"},"modified":"2020-07-17T17:04:54","modified_gmt":"2020-07-17T15:04:54","slug":"vaksina-potenciale-e-zhvilluar-nga-shkencetari-turk-do-te-filloje-te-testohet-ne-kine","status":"publish","type":"post","link":"https:\/\/alb.shekulliagency.com\/?p=33157","title":{"rendered":"Vaksina potenciale e zhvilluar nga shkenc\u00ebtari turk do t\u00eb filloj\u00eb t\u00eb testohet n\u00eb Kin\u00eb"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"864\" height=\"471\" src=\"http:\/\/alb.shekulliagency.com\/wp-content\/uploads\/2017\/09\/thumbs_b_c_83a00d7de1d46577bf32fa3c3614ca67-1.jpg\" alt=\"\" class=\"wp-image-21685\" srcset=\"https:\/\/alb.shekulliagency.com\/wp-content\/uploads\/2017\/09\/thumbs_b_c_83a00d7de1d46577bf32fa3c3614ca67-1.jpg 864w, https:\/\/alb.shekulliagency.com\/wp-content\/uploads\/2017\/09\/thumbs_b_c_83a00d7de1d46577bf32fa3c3614ca67-1-300x164.jpg 300w, https:\/\/alb.shekulliagency.com\/wp-content\/uploads\/2017\/09\/thumbs_b_c_83a00d7de1d46577bf32fa3c3614ca67-1-768x419.jpg 768w\" sizes=\"(max-width: 864px) 100vw, 864px\" \/><\/figure>\n\n\n\n<p>Vaksina eksperimentale kund\u00ebr koronavirusit t\u00eb ri (COVID-19), e zhvilluar nga firma e bioteknologjis\u00eb BioNTech n\u00eb Gjermani, e bashk\u00ebthemeluar nga shkenc\u00ebtari turk Prof. Dr. U\u011fur \u015eahin, pas Gjermanis\u00eb dhe SHBA-s\u00eb, do t\u00eb filloj\u00eb t\u00eb testohet edhe te njer\u00ebzit n\u00eb Kin\u00eb. <\/p>\n\n\n\n<p>Sipas nj\u00eb lajmi n\u00eb faqen e internetit &#8220;Clinical Trials Arena&#8221;, kompania farmaceutike Fosun Pharma, me seli n\u00eb Shanghai, ka marr\u00eb miratimin nga Administrata Komb\u00ebtare Kineze e Produkteve Mjek\u00ebsore (NMPA) p\u00ebr provat klinike t\u00eb faz\u00ebs s\u00eb par\u00eb t\u00eb vaksin\u00ebs n\u00eb zhvillim e sip\u00ebr &#8220;BNT162b1&#8221;.<\/p>\n\n\n\n<p>Kompania, e cila ka marr\u00eb licenc\u00ebn p\u00ebr zhvillimin dhe prodhimin serik t\u00eb vaksin\u00ebs n\u00eb Kin\u00eb, synon t\u00eb filloj\u00eb faz\u00ebn e dyt\u00eb dhe t\u00eb tret\u00eb t\u00eb testimit klinik n\u00eb fund t\u00eb k\u00ebtij muaji, me m\u00eb shum\u00eb se 30 mij\u00eb persona q\u00eb do t\u00eb testohen.<\/p>\n\n\n\n<p>Vaksina e bazuar n\u00eb Acidin Ribonukleik (MRNA) p\u00ebrmban nj\u00eb p\u00ebrb\u00ebr\u00ebs mbrojt\u00ebs q\u00eb synon krijimin e imunitetit ndaj COVID-19 tek njer\u00ebzit e mosh\u00ebs 18 vje\u00e7 dhe m\u00eb t\u00eb vjet\u00ebr.<\/p>\n\n\n\n<p>Vaksina potenciale tashm\u00eb \u00ebsht\u00eb testuar te njer\u00ebzit n\u00eb Gjermani dhe SHBA. N\u00eb provat e faz\u00ebs s\u00eb par\u00eb t\u00eb kryera me nj\u00eb num\u00ebr t\u00eb vog\u00ebl njer\u00ebzish, u raportua se vaksina ishte e sigurt dhe arriti t\u00eb krijoj\u00eb imunitet te t\u00eb testuarit.<\/p>\n\n\n\n<p>Kompania BioNTech, e themeluar n\u00eb vitin 2008 n\u00eb Mainz t\u00eb Gjermanis\u00eb, punon p\u00ebr t\u00eb zhvilluar ila\u00e7e p\u00ebr disa s\u00ebmundje, p\u00ebrfshir\u00eb kancerin. BioNTech ofroi aksionet e saj p\u00ebr publikun e gjer\u00eb n\u00eb burs\u00ebn Nasdaq n\u00eb SHBA n\u00eb tetor t\u00eb vitit 2019 dhe tuboi nj\u00eb investim prej 150 milion\u00eb dollar\u00ebsh.<\/p>\n\n\n\n<p>Kompania ka b\u00ebr\u00eb marr\u00ebveshje partneriteti me gjigantin farmaceutik amerikan Pfizer dhe at\u00eb kinez Fosun Pharma p\u00ebr t\u00eb zhvilluar dhe prodhuar vaksin\u00eb kund\u00ebr COVID-19.<\/p>\n\n\n\n<p><strong>Provat klinike realizohen n\u00eb 3 faza<\/strong><\/p>\n\n\n\n<p>Q\u00eb nj\u00eb vaksin\u00eb t\u00eb p\u00ebrdoret gjer\u00ebsisht, duhet t\u00eb testohet tek njer\u00ebzit n\u00eb tri faza.<\/p>\n\n\n\n<p>N\u00eb faz\u00ebn e par\u00eb t\u00eb provave klinike, hetohet n\u00ebse vaksina \u00ebsht\u00eb e sigurt dhe ka efekte an\u00ebsore t\u00eb mundshme n\u00eb nj\u00eb num\u00ebr t\u00eb vog\u00ebl t\u00eb subjekteve t\u00eb sh\u00ebndetsh\u00ebm vullnetar\u00eb.<\/p>\n\n\n\n<p>N\u00eb faz\u00ebn e dyt\u00eb testohet efektiviteti i vaksin\u00ebs, besueshm\u00ebria e s\u00eb cil\u00ebs tashm\u00eb \u00ebsht\u00eb konfirmuar n\u00eb faz\u00ebn e m\u00ebparshme, n\u00eb m\u00eb shum\u00eb se 100 subjekte.<\/p>\n\n\n\n<p>N\u00eb faz\u00ebn e tret\u00eb dhe t\u00eb fundit, i nj\u00ebjti proces p\u00ebrs\u00ebritet me disa mij\u00ebra subjekte. I gjith\u00eb ky proces mund t\u00eb zgjas\u00eb me muaj apo edhe vite.<\/p>\n\n\n\n<p>Ndryshe, sipas t\u00eb dh\u00ebnave t\u00eb Organizat\u00ebs Bot\u00ebrore t\u00eb Sh\u00ebndet\u00ebsis\u00eb, 23 vaksina n\u00eb zhvillim e sip\u00ebr kund\u00ebr COVID-19 jan\u00eb n\u00eb faz\u00ebn e zhvillimit para-klinik dhe 140 t\u00eb tjera jan\u00eb n\u00eb faz\u00ebn e testimit klinik.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vaksina eksperimentale kund\u00ebr koronavirusit t\u00eb ri (COVID-19), e zhvilluar nga firma e bioteknologjis\u00eb BioNTech n\u00eb Gjermani, e bashk\u00ebthemeluar nga shkenc\u00ebtari turk Prof. Dr. U\u011fur \u015eahin, pas Gjermanis\u00eb dhe SHBA-s\u00eb, do&#8230;<\/p>\n","protected":false},"author":1,"featured_media":21685,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-33157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lajme"],"_links":{"self":[{"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/posts\/33157"}],"collection":[{"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33157"}],"version-history":[{"count":1,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/posts\/33157\/revisions"}],"predecessor-version":[{"id":33158,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/posts\/33157\/revisions\/33158"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/media\/21685"}],"wp:attachment":[{"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}